BPA Call 36E79720A0015-36C24122N0082
Award Date 10/8/21
Potential Completion Date 10/31/21
Potential Value $15K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order is valued at $18,125.50 and provides the VA's Veterans Health Administration (VHA) with the oncology medication BALVERSA (erdafitinib) to support healthcare services for veterans. The delivery order is placed against Janssen Biotech's existing $3.1 billion Federal Supply Schedule (FSS) contract for Pharmaceuticals and...
- This is a firm fixed price delivery order contract awarded to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., by the Department of Veterans Affairs (VA). The contract has an ultimate completion date of November 22, 2024 and a ceiling value of $13,639.07. The contract is for the provision of the oncology drug BALVERSA (erdafitinib) to support healthcare services for veterans through the VA's Veterans Health Administration (VHA). Janssen Biotech is a major pharmaceutical...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs to support veteran healthcare programs. The $22,053.66...
- This federal contract award is a firm fixed price delivery order issued by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer. The $18,803.91 contract is for the delivery of BALVERSA 4 MG, an oncology medication, to support healthcare services for veterans. The contract has no set-aside designation and is issued against the VA's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs, which is...
- This is a federal contract award issued by the U.S. Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The contract, valued at $90,543.72, is for the delivery of BALVERSA (erdafitinib), a cancer treatment drug, to support healthcare services for veterans. The contract is a Blanket Purchase Agreement (BPA) call order under a larger $3.7 million single-award BPA established in August 2020, which allows various VA Integrated Service Networks...
- This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a major pharmaceutical manufacturer. The $13,639.07 firm fixed price contract is for the delivery of BALVERSA 3 MG, an oncology medication, to support the VA's Veterans Health Administration (VHA) and its Veterans Integrated Service Networks (VISNs). Janssen Biotech holds several significant federal contracts with the VA, including a $3.1...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the pharmaceutical product BALVERSA 4MG TABS. The $17,642.95 order was issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract (FSS-61-IB) and has a completion date of June 30, 2024. Janssen Biotech Inc. is a for-profit manufacturer of specialty medications, including...
- This is a firm fixed price delivery order awarded by the Department of Veterans Affairs Veterans Health Administration to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order, valued at $62,248.81, is for the cancer treatment drug BALVERSA to support healthcare services for veterans. The delivery order was issued under Janssen's General Services Administration Multiple Award Schedule Contract for Pharmaceuticals and Drugs (FSS-61-IB), which allows the VA to efficiently...
- The Department of Veterans Affairs, through Veterans Integrated Service Network 5, awarded a $20,295.20 firm fixed-price delivery order to Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.) for BALVERSA 4 MG, a specialized oncology medication used in cancer treatment. This delivery order was issued on March 20, 2026, with an ultimate completion date of March 24, 2026, and will be performed in Carrollton, Texas. The award carries no set-aside designation, reflecting Janssen...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer. The contract provides BALVERSA 4MG and 5MG tablets, an oncology medication, to the VA's Veterans Health Administration (VHA) through a Firm Fixed Price Delivery Order. The contract has a ceiling value of $55,400.54 and an ultimate completion date of October 31, 2023. This contract is not designated as a set-aside....